The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors
- PMID: 1638540
The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors
Abstract
Available evidence suggests that, among hematological malignancies, p53 is most often mutated in Burkitt's lymphoma (BL). However, much of the published data is based on cell lines. We have, therefore, analyzed BL biopsies to determine more accurately the frequency and pattern of p53 mutations in primary tumors and to determine whether there are differences among the various subtypes of BL. Among 27 BL biopsies from South Africa, we have observed mutations in the p53 gene (exons 5 through 8) in 37% of tumors. The higher frequency of mutations in cell lines (70%) suggests that mutation of p53 may be associated with tumor progression. Summarizing available data we conclude that the presence of mutated p53 in BL is independent of the geographic origin of the tumor, the 8;14 chromosomal breakpoint locations and Epstein-Barr virus association. We also find that the mutational spectrum of p53 in BL differs from that observed in nonlymphoid tumors. More than 50% of mutations in BL are clustered in a small stretch of 33 amino acids (codons 213 to 248). Interestingly, codon 213 appears to be as frequently mutated as codon 248. Conversely, codon 273, often mutated in solid tumors, is rarely involved in BL.
Similar articles
-
Mutational analysis of p53 in 16 cases of acute lymphoblastic leukemia and Burkitt's lymphoma.Haematologica. 1997 Sep-Oct;82(5):550-4. Haematologica. 1997. PMID: 9407719
-
Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.Oncogene. 1993 Oct;8(10):2741-8. Oncogene. 1993. PMID: 8397370
-
A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.Cancer Res. 1995 Apr 1;55(7):1431-5. Cancer Res. 1995. PMID: 7882347
-
Pooled analysis of p53 mutations in hematological malignancies.Hum Mutat. 1998;12(1):4-18. doi: 10.1002/(SICI)1098-1004(1998)12:1<4::AID-HUMU2>3.0.CO;2-G. Hum Mutat. 1998. PMID: 9633814 Review.
-
Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis.Leuk Lymphoma. 1998 Jul;30(3-4):257-67. doi: 10.3109/10428199809057539. Leuk Lymphoma. 1998. PMID: 9713958 Review.
Cited by
-
Somatic inactivation of Tp53 in hematopoietic stem cells or thymocytes predisposes mice to thymic lymphomas with clonal translocations.Cell Cycle. 2013 Oct 15;12(20):3307-16. doi: 10.4161/cc.26299. Epub 2013 Sep 9. Cell Cycle. 2013. PMID: 24036547 Free PMC article.
-
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9. Biomark Res. 2024. PMID: 39538363 Free PMC article. Review.
-
Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.Cell Cycle. 2010 Mar 1;9(5):901-8. doi: 10.4161/cc.9.5.10840. Epub 2010 Mar 3. Cell Cycle. 2010. PMID: 20160479 Free PMC article.
-
Mechanisms involved in Burkitt's tumor formation.Clin Transl Oncol. 2008 May;10(5):250-5. doi: 10.1007/s12094-008-0193-x. Clin Transl Oncol. 2008. PMID: 18490240 Review.
-
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.Cancer Cell. 2012 Aug 14;22(2):167-79. doi: 10.1016/j.ccr.2012.06.012. Cancer Cell. 2012. PMID: 22897848 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous